Positive AZUR-1 data de-risks a new indication for Jemperli and supports accelerated regulatory filings. Traders should watch for FDA acceptance of a supplemental BLA and potential approval timeline (likely 2027). The data also strengthens GSK's immuno-oncology positioning. Monitor for detailed results at a future scientific congress.
Drug in focus
GSK drug pipeline →Jemperli
● Neutral Named in this 6-K- Impact
- Phase
- Approved (Phase 3 / registrational Phase 2 for additional indications)
- Time to market
- Already marketed (first FDA approval April 2021). Potential label expansion in dMMR/MSI-H rectal cancer would follow AZUR-1 data (H2 2026) and subsequent BLA filing.
- Next catalyst
- None dated
What to watchWatch for AZUR-1 Phase 2 registrational data in H2 2026, a positive readout (extending the 100% cCR rate seen in the MSK-collaboration study) could lead to an FDA filing for rectal cancer and support the ~$2.5B+ peak sales consensus. Be aware of the AnaptysBio royalty dispute going to trial in July 2026, which could alter Jemperli's economics. For a diversified phyla stock like GSK, Jemperli is a growth driver in oncology but not a stand-alone thesis.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $52.29entry
- T+1 · 4mo ago −1.99%α −2.34% · $51.25
- T+5 · 4mo ago −1.01%α −0.23% · $51.76
- T+20 · 3mo ago −0.25%α −3.43% · $52.16
- T+60 · 6w ago −10.88%α −14.88% · $46.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in dMMR/MSI-H locally advanced rectal cancer. The trial met its primary objective, showing a sustained clinical complete response rate at 12 months (cCR12), supporting the potential to eliminate or delay chemotherapy, radiation, and surgery. GSK plans to share data with global regulators, including accelerated review in the US, where Jemperli already has Breakthrough Therapy and Fast Track designations.
Key Facts
- AZUR-1 phase II trial (n=154) met primary endpoint: sustained clinical complete response at 12 months (cCR12) in dMMR/MSI-H locally advanced rectal cancer
- Results support potential for Jemperli to become first immunotherapy to eliminate need for chemotherapy, radiation, and surgery in some patients
- Data to be shared with health authorities for regulatory review, including accelerated review in the US
- Jemperli already has Breakthrough Therapy and Fast Track designations from FDA in this setting
- Safety profile consistent with known profile across solid tumors
- Jemperli is not currently approved anywhere for rectal cancer
Financial Impact
Expands Jemperli's addressable market into an estimated 36,500-73,000 annual dMMR/MSI-H rectal cancer patients globally; revenue contribution depends on approval and pricing, but adds to GSK's oncology pipeline value
Risk Factors
- Regulatory approval not guaranteed; FDA may require additional confirmatory data from a randomized trial
- Competition from other PD-1 inhibitors (e.g., Keytruda, Opdivo) already approved in dMMR/MSI-H solid tumors
- Single-arm phase II design may limit regulatory acceptance outside the US
- Commercial uptake depends on pricing, reimbursement, and physician adoption of immunotherapy-only approach
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006614 |
| Document: 0001654954-26-006614-index-headers.html | 0001654954-26-006614 |
| Document: 0001654954-26-006614-index.html | 0001654954-26-006614 |
| Document: 0001654954-26-006614.txt | 0001654954-26-006614 |
Track record
64 reports on GSK
9 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers